Medicilon

21/12/2024

🎄 Season's Greetings from Medicilon! 🎉

As we close out 2024, we reflect on a remarkable year full of innovation and growth. From opening our new R&D innovation center in Boston, celebrating our 20th anniversary to successfully advancing over 490 drug discovery projects into the clinical stage, none of it would have been possible without the trust and collaboration of our valued clients and partners!

Thank you for being a part of our journey. At Medicilon, we can assist you every step of the way from , to . We are backed by exceptionally experienced scientific team alone with cutting-edge technologies and platforms.
To inquire more please reach out to marketing@medicilon.com

We look forward to another year of exciting breakthroughs, growth, and continued partnership! Wishing you all a joyful holiday season and a prosperous new year!

17/12/2024

🌟Medicilon Taiwan Workshop🌟
🚀New Approaches to Facilitate Drug Discovery and Development

Medicilon - Your Comprehensive Partner for Pharmaceutical R&D

As a leading CRO, Medicilon provides extensive R&D solutions for global pharmaceutical companies, emerging biotech companies, and research institutions. With over 20 years of experience, we have supported more than 2,000 clients and contributed to the IND approval of over 490 drugs.

👉 Learn More About Our Services: https://www.medicilon.com/services/

13/12/2024

🚀Medicilon Supports Jemincare's JMX-2002 Liposome Injection Trial

JMX-2002 Injection enhances drug targeting and while minimizing damage to healthy tissues. Utilizing liposomes as carriers, this innovative improves treatment delivery and effectiveness for solid tumors, providing a promising alternative to traditional therapies with fewer side effects.

Medicilon has played a crucial role in the development of JMX-2002, offering comprehensive preclinical support through its specialized liposome drug development platform.

This platform covers lipid synthesis, liposome preparation, formulation screening, safety evaluation, , and regulatory support, helping to optimize the drug’s efficacy and safety profile.

👇 Learn More About Our Role in This Groundbreaking Development

Medicilon has been instrumental in advancing JMX-2002's development, providing comprehensive preclinical support through its specialized liposome drug development platform.

11/12/2024

🚀Medicilon Supports Partner Jemincare in Securing from for JM045 Sustained-Release Microspheres

JM045 is a gonadotropin-releasing hormone (GnRH) analog with a novel mechanism designed to offer a better therapeutic option for patients in need of androgen deprivation therapy.

, as a trusted partner, provided studies and -compliant evaluations, playing an instrumental role in advancing the drug development process.

👇 Learn More About Our Role in This Groundbreaking Development

Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon provided pharmacokinetic studies and GLP-compliant safety evaluations for this development.

09/12/2024

HRS-9563, a cutting-edge Class I drug, has been approved for the treatment of . As a critical cardiovascular condition, hypertension affects millions worldwide, often with limited therapeutic options. HRS-9563 targets specific genetic sequences, inhibiting key proteins responsible for high blood pressure. This represents a promising new direction in hypertension management.

worked alongside Hengrui Pharmaceuticals to secure the approval of HRS-9563, providing vital studies and -compliant evaluations.

👇 Learn More About Our Role in This Groundbreaking Development

Medicilon played a strategic role in the development of HRS-9563 by providing preclinical pharmacokinetics studies and GLP-compliant safety evaluations.

04/12/2024

PDXO Model: A Significant Advancement in Precision Oncology

Patient-Derived Xenograft Organoids (PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues. Constructed using methods like those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy. These models surpass traditional 2D cell cultures by preserving the complex internal architecture of tumors, offering superior predictive power for selecting clinically relevant in vivo models and expediting drug development. PDXOs effectively bridge the gap between in vivo PDX models and in vitro tumor studies, combining the strengths of both approaches.

Applicable across various cancer types-including breast, colorectal, lung, and more-PDXOs serve as a valuable platform for investigating tumor heterogeneity, drug responses, resistance mechanisms, and metastasis.
At Medicilon, we have successfully developed nine PDXO models encompassing colorectal, pancreatic, gastric, leukemia, and prostate cancers. Each model undergoes stringent quality control processes, including the removal of mouse-derived fibroblasts, ensuring stable passaging, and cryopreservation.

Learn more: https://www.medicilon.com/services/pdxo-model/

As this field continues to advance, the transformative potential of PDXOs in cancer research and treatment is immense.
Models
organoid models